Cargando…

Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center

Treatment of glioblastoma (GBM) consists of microsurgical resection followed by concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of a specialized neuro-oncology care c...

Descripción completa

Detalles Bibliográficos
Autores principales: Haj, Amer, Doenitz, Christian, Schebesch, Karl-Michael, Ehrensberger, Denise, Hau, Peter, Putnik, Kurt, Riemenschneider, Markus J., Wendl, Christina, Gerken, Michael, Pukrop, Tobias, Brawanski, Alexander, Proescholdt, Martin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789336/
https://www.ncbi.nlm.nih.gov/pubmed/29295569
http://dx.doi.org/10.3390/brainsci8010005
_version_ 1783296253798383616
author Haj, Amer
Doenitz, Christian
Schebesch, Karl-Michael
Ehrensberger, Denise
Hau, Peter
Putnik, Kurt
Riemenschneider, Markus J.
Wendl, Christina
Gerken, Michael
Pukrop, Tobias
Brawanski, Alexander
Proescholdt, Martin A.
author_facet Haj, Amer
Doenitz, Christian
Schebesch, Karl-Michael
Ehrensberger, Denise
Hau, Peter
Putnik, Kurt
Riemenschneider, Markus J.
Wendl, Christina
Gerken, Michael
Pukrop, Tobias
Brawanski, Alexander
Proescholdt, Martin A.
author_sort Haj, Amer
collection PubMed
description Treatment of glioblastoma (GBM) consists of microsurgical resection followed by concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of a specialized neuro-oncology care center (NOC) has enabled the implementation of a large technical portfolio including functional imaging, awake craniotomy, PET scanning, fluorescence-guided resection, and integrated postsurgical therapy. This study analyzed whether the technically improved neurosurgical treatment structure yields a higher rate of complete resection, thus ultimately improving patient outcome. Patients and methods: The study included 149 patients treated surgically for newly diagnosed GBM. The neurological performance score (NPS) and the Karnofsky performance score (KPS) were measured before and after resection. The extent of resection (EOR) was volumetrically quantified. Patients were stratified into two subcohorts: treated before (A) and after (B) the foundation of the Regensburg NOC. The EOR and the PFS and OS were evaluated. Results: Prognostic factors for PFS and OS were age, preoperative KPS, O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, isocitrate dehydrogenase 1 (IDH1) mutation status and EOR. Patients with volumetrically defined complete resection had significantly better PFS (9.4 vs. 7.8 months; p = 0.042) and OS (18.4 vs. 14.5 months; p = 0.005) than patients with incomplete resection. The frequency of transient or permanent postoperative neurological deficits was not higher after complete resection in both subcohorts. The frequency of complete resection was significantly higher in subcohort B than in subcohort A (68.2% vs. 34.8%; p = 0.007). Accordingly, subcohort B showed significantly longer PFS (8.6 vs. 7.5 months; p = 0.010) and OS (18.7 vs. 12.4 months; p = 0.001). Multivariate Cox regression analysis showed complete resection, age, preoperative KPS, and MGMT promoter status as independent prognostic factors for PFS and OS. Our data show a higher frequency of complete resection in patients with GBM after the establishment of a series of technical developments that resulted in significantly better PFS and OS without increasing surgery-related morbidity.
format Online
Article
Text
id pubmed-5789336
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57893362018-02-02 Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center Haj, Amer Doenitz, Christian Schebesch, Karl-Michael Ehrensberger, Denise Hau, Peter Putnik, Kurt Riemenschneider, Markus J. Wendl, Christina Gerken, Michael Pukrop, Tobias Brawanski, Alexander Proescholdt, Martin A. Brain Sci Article Treatment of glioblastoma (GBM) consists of microsurgical resection followed by concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of a specialized neuro-oncology care center (NOC) has enabled the implementation of a large technical portfolio including functional imaging, awake craniotomy, PET scanning, fluorescence-guided resection, and integrated postsurgical therapy. This study analyzed whether the technically improved neurosurgical treatment structure yields a higher rate of complete resection, thus ultimately improving patient outcome. Patients and methods: The study included 149 patients treated surgically for newly diagnosed GBM. The neurological performance score (NPS) and the Karnofsky performance score (KPS) were measured before and after resection. The extent of resection (EOR) was volumetrically quantified. Patients were stratified into two subcohorts: treated before (A) and after (B) the foundation of the Regensburg NOC. The EOR and the PFS and OS were evaluated. Results: Prognostic factors for PFS and OS were age, preoperative KPS, O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, isocitrate dehydrogenase 1 (IDH1) mutation status and EOR. Patients with volumetrically defined complete resection had significantly better PFS (9.4 vs. 7.8 months; p = 0.042) and OS (18.4 vs. 14.5 months; p = 0.005) than patients with incomplete resection. The frequency of transient or permanent postoperative neurological deficits was not higher after complete resection in both subcohorts. The frequency of complete resection was significantly higher in subcohort B than in subcohort A (68.2% vs. 34.8%; p = 0.007). Accordingly, subcohort B showed significantly longer PFS (8.6 vs. 7.5 months; p = 0.010) and OS (18.7 vs. 12.4 months; p = 0.001). Multivariate Cox regression analysis showed complete resection, age, preoperative KPS, and MGMT promoter status as independent prognostic factors for PFS and OS. Our data show a higher frequency of complete resection in patients with GBM after the establishment of a series of technical developments that resulted in significantly better PFS and OS without increasing surgery-related morbidity. MDPI 2017-12-25 /pmc/articles/PMC5789336/ /pubmed/29295569 http://dx.doi.org/10.3390/brainsci8010005 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Haj, Amer
Doenitz, Christian
Schebesch, Karl-Michael
Ehrensberger, Denise
Hau, Peter
Putnik, Kurt
Riemenschneider, Markus J.
Wendl, Christina
Gerken, Michael
Pukrop, Tobias
Brawanski, Alexander
Proescholdt, Martin A.
Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
title Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
title_full Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
title_fullStr Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
title_full_unstemmed Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
title_short Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
title_sort extent of resection in newly diagnosed glioblastoma: impact of a specialized neuro-oncology care center
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789336/
https://www.ncbi.nlm.nih.gov/pubmed/29295569
http://dx.doi.org/10.3390/brainsci8010005
work_keys_str_mv AT hajamer extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT doenitzchristian extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT schebeschkarlmichael extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT ehrensbergerdenise extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT haupeter extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT putnikkurt extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT riemenschneidermarkusj extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT wendlchristina extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT gerkenmichael extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT pukroptobias extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT brawanskialexander extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter
AT proescholdtmartina extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter